Skip to main content

Table 1 Descriptive analysis of baseline demographic characteristics for BREEZE-AD1, BREEZE-AD2, and BREEZE-AD5

From: Psychometric properties of the itch numeric rating scale, skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with moderate-to-severe atopic dermatitis

Characteristics

BREEZE-AD1 (N = 624)

BREEZE-AD2 (N = 615)

BREEZE-AD5 (N = 440)

Age, years

35.6 (12.81)

34.7 (12.77)

39.5 (16.06)

Sex, n (%)

Male

391 (62.7)

381 (62.0)

224 (50.9)

Female

233 (37.3)

234 (38.0)

216 (49.1)

Race, n (%)

White

366 (58.9)

421 (68.5)

251 (57.3)

African American

2 (0.3)

0 (0)

80 (18.3)

Asian

189 (30.4)

183 (29.8)

81 (18.5)

Other

64 (10.3)

11 (1.8)

26 (5.9)

Alcohol use, n (%)

Never

214 (34.3)

220 (35.8)

103 (23.4)

Current

381 (61.1)

353 (57.4)

291 (66.1)

Former

29 (4.6)

42 (6.8)

46 (10.5)

Tobacco use, n (%)

Never

394 (63.1)

389 (63.3)

276 (62.7)

Current

158 (25.3)

155 (25.2)

80 (18.2)

Former

72 (11.5)

71 (11.5)

84 (19.1)

Duration since AD diagnosis, years

25.7 (15.10)

24.2 (13.86)

23.6 (16.65)

Age at time of AD diagnosis, years

10.2 (14.54)

10.8 (14.22)

15.9 (20.30)

IGA of 3, n (%)

363 (58.2)

305 (49.7)

256 (58.2)

IGA of 4, n (%)

261 (41.8)

309 (50.3)

184 (41.8)

EASI

30.9 (12.45)

33.5 (13.44)

27.1 (11.29)

BSA

51.0 (22.34)

53.5 (22.62)

40.9 (22.73)

Itch NRS

6.5 (2.09)

6.6 (2.17)

7.2 (2.17)

Skin Pain NRS

5.8 (2.47)

6.05 (2.55)

6.56 (2.63)

ADSS Item 2

3.0 (4.67)

1.8 (2.31)

2.3 (2.89)

DLQI

13.6 (7.27)

14.4 (8.09)

14.7 (7.28)

PGI-S-AD

3.9 (0.82)

3.9 (0.85)

4.0 (0.85)

POEM

20.7 (5.59)

20.4 (6.26)

21.3 (5.62)

  1. Data are mean (standard deviation) unless stated otherwise
  2. AD, atopic dermatitis; ADSS, Atopic Dermatitis Sleep Scale; BSA, body surface area; DLQI, Dermatology Life Quality Index; EASI, Eczema Area and Severity Index; IGA, Investigator’s Global Assessment; N, number of total patients, NRS, numeric rating scale; PGI-S-AD, Patient Global Impression of Severity–Atopic Dermatitis; POEM, Patient Oriented Eczema Measure; PRO, patient-reported outcome